biostudies-literatureUnknown11(1)Dalal JDr. Reddy&apos;s Laboratories, Hyderabad, India<h4>Introduction</h4>Fondaparinux is a low molecular weight heparin anticoagulant used to manage the full spectrum of acute coronary syndrome (ACS) patients and has proved its efficacy and safety in multiple clinical trials. However, there are limited data available showing whether the same results could be reproduced in real-world practice on an Indian population. Our objective was to determine the effectiveness and tolerability of fondaparinux in the management of symptomatic ACS in real-world clinical practice.<h4>Methods</h4>The EMR data of hospitalized ACS patients (n = 611), from January 2015 to January 2020, representing UA or NSTEMI or STEMI and were prescribed fondaparinux (2.5 mg once daily) to manage ACS were analyzed. The effectiveness was analyzed as recurrence of ACS and toleCardiology and therapy129-141https://www.ebi.ac.uk/biostudies/studies/S-EPMC8933594biostudies-literatureEvaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population.PMC8933594Kumar ASMeel BMane AHiremath JSubramaniyan AKhan MYPandit SSathe SDalal JMohan JCGaurav KfalseEvaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population.<h4>Introduction</h4>Fondaparinux is a low molecular weight heparin anticoagulant used to manage the full spectrum of acute coronary syndrome (ACS) patients and has proved its efficacy and safety in multiple clinical trials. However, there are limited data available showing whether the same results could be reproduced in real-world practice on an Indian population. Our objective was to determine the effectiveness and tolerability of fondaparinux in the management of symptomatic ACS in real-world clinical practice.<h4>Methods</h4>The EMR data of hospitalized ACS patients (n = 611), from January 2015 to January 2020, representing UA or NSTEMI or STEMI and were prescribed fondaparinux (2.5 mg once daily) to manage ACS were analyzed. The effectiveness was analyzed as recurrence of ACS and tole2022-01-01T00:00:00Z2022 Mar2025-05-31T22:19:52.968Z2025-05-31T22:19:52.968ZS-EPMC89335943513859510.1007/s40119-022-00253-x